(Q33411075)

English

Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Evaluation of the QTc prolongation potential of a monoclonal antibody, siltuximab, in patients with monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, or low-volume multiple myeloma (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

author name string

Sheeba K Thomas

1

1 reference

Europe PubMed Central

26 July 2017

Alexander Suvorov

2

1 reference

Europe PubMed Central

26 July 2017

Lucien Noens

3

1 reference

Europe PubMed Central

26 July 2017

Oleg Rukavitsin

4

1 reference

Europe PubMed Central

26 July 2017

Joseph Fay

5

1 reference

Europe PubMed Central

26 July 2017

Ka Lung Wu

6

1 reference

Europe PubMed Central

26 July 2017

Todd M Zimmerman

7

1 reference

Europe PubMed Central

26 July 2017

Helgi van de Velde

8

1 reference

Europe PubMed Central

26 July 2017

Rajesh Bandekar

9

1 reference

Europe PubMed Central

26 July 2017

Thomas A Puchalski

10

1 reference

Europe PubMed Central

26 July 2017

Ming Qi

11

1 reference

Europe PubMed Central

26 July 2017

Clarissa Uhlar

12

1 reference

Europe PubMed Central

26 July 2017

Olga S Samoylova

13

1 reference

Europe PubMed Central

26 July 2017

publication date

23 October 2013

1 reference

Europe PubMed Central

26 July 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

26 July 2017

73

1 reference

Europe PubMed Central

26 July 2017

1

1 reference

Europe PubMed Central

26 July 2017

35-42

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s00280-013-2314-7

0 references

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2314-7

21 January 2018

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2314-7

21 January 2018

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2314-7

21 January 2018

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2314-7

21 January 2018

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2314-7

21 January 2018

Interleukin 6 is essential for in vivo development of B lineage neoplasms

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2314-7

21 January 2018

A novel monoclonal antibody screening method using the Luminex-100 microsphere system

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2314-7

21 January 2018

A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2314-7

21 January 2018

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2314-7

21 January 2018

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2314-7

21 January 2018

Smoldering, asymptomatic stage 1, and indolent myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2314-7

21 January 2018

Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2314-7

21 January 2018

A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2314-7

21 January 2018

Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2314-7

21 January 2018

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2314-7

21 January 2018

Identifiers

10.1007/S00280-013-2314-7

1 reference

Europe PubMed Central

26 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33411075&oldid=1638816014"